<DOC>
	<DOCNO>NCT02269579</DOCNO>
	<brief_summary>To assess impact moderate hepatic impairment cytarabine daunorubicin pharmacokinetics metabolites follow administration CPX-351 .</brief_summary>
	<brief_title>Pharmacokinetic Pharmacodynamic Assessment Treatment With CPX-351 ( Cytarabine : Daunorubicin ) Liposome Injection Acute Leukemias MDS Patients With Moderate Hepatic Impairment</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Ability understand voluntarily sign informed consent form Age ≥ 18 ≤ 80 year time signing informed consent form Life expectancy least 3 month Pathological confirmation bone marrow document follow : Newly Diagnosed De novo AML accord WHO criteria except Acute Promyelocytic Leukemia patient know favorable cytogenetics Newly Diagnosed Secondary AML define history antecedent hematologic disorder ( myelodysplastic syndrome [ MDS ] , myeloproliferative disease [ MPD ] history cytotoxic treatment nonhematologic malignancy ) Patients relapsed/refractory AML regardless cytogenetic risk Patients relapsed/refractory ALL Patients MDS ( IPSS score ≥ 1.5 ) Eastern Cooperative Oncology Group ( ECOG ) performance status score 02 Able adhere study visit schedule protocol requirement Laboratory value fulfil follow : Serum creatinine ≤ 2.0mg/dL . Hepatic function score 79 point accord ChildPugh System Serum alanine aminotransferase aspartate aminotransferase &lt; 3 time ULN . Note : If elevate liver enzymes related disease ; contact medical monitor discus . Cardiac ejection fraction ≥50 % ECHO MUGA Patients second malignancy remission may eligible clinical evidence disease stability period great 6 month cytotoxic chemotherapy , document imaging , tumor marker study , etc. , screen . Patients maintain longterm nonchemotherapy treatment , e.g. , hormonal therapy , eligible . All men woman must agree practice effective contraception study period otherwise document infertile . Patients history and/or current evidence myocardial impairment ( e.g . cardiomyopathy , ischemic heart disease , significant valvular dysfunction , hypertensive heart disease , congestive heart failure ) result heart failure New York Heart Association Criteria ( Class III IV stag ) Newly diagnose patient Acute promyelocytic leukemia [ ( 15 ; 17 ) ] favorable cytogenetics , include ( 8 ; 21 ) inv16 Clinical evidence active CNS leukemic involvement Chemotherapy investigational anticancer therapeutic drug within 1 week prior study entry . AEs prior therapy must resolve stabilized interference assessment efficacy safety ; event rapidly proliferative disease , however , use hydroxyurea permit 12 hour study entry . Patients prior bone marrow stem cell transplant , consider inclusion , discuss medical monitor first . Any serious medical condition psychiatric illness would prevent patient provide informed consent Patients prior cumulative anthracycline exposure great 368 mg/m2 daunorubicin ( equivalent ) Active uncontrolled infection . Patients infection receive treatment ( antibiotic , antifungal antiviral treatment ) may enter study must afebrile hemodynamically stable ≥72 hr . Patients fever believe due leukemia MDS eligible provide thorough infection workup negative patient clinically hemodynamically stable . Pregnant lactate woman Hypersensitivity cytarabine , daunorubicin liposomal product History Wilson 's disease copperrelated metabolic disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Newly Diagnosed AML</keyword>
	<keyword>Secondary AML</keyword>
	<keyword>Relapsed/Refractory AML</keyword>
	<keyword>Relapsed/Refractory ALL</keyword>
</DOC>